1. Home
  2. SPT vs RZLT Comparison

SPT vs RZLT Comparison

Compare SPT & RZLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

SPT

Sprout Social Inc

HOLD

Current Price

$5.54

Market Cap

327.6M

Sector

Technology

ML Signal

HOLD

Logo Rezolute Inc. (NV)

RZLT

Rezolute Inc. (NV)

HOLD

Current Price

$2.85

Market Cap

326.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SPT
RZLT
Founded
2010
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
327.6M
326.4M
IPO Year
2019
2011

Fundamental Metrics

Financial Performance
Metric
SPT
RZLT
Price
$5.54
$2.85
Analyst Decision
Buy
Strong Buy
Analyst Count
8
6
Target Price
$12.38
$9.67
AVG Volume (30 Days)
1.7M
3.0M
Earning Date
05-07-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
32.11
26.32
EPS
N/A
N/A
Revenue
$457,547,000.00
N/A
Revenue This Year
$9.03
N/A
Revenue Next Year
$8.83
N/A
P/E Ratio
N/A
N/A
Revenue Growth
12.72
N/A
52 Week Low
$5.39
$1.07
52 Week High
$24.74
$11.46

Technical Indicators

Market Signals
Indicator
SPT
RZLT
Relative Strength Index (RSI) 34.76 48.31
Support Level N/A $2.87
Resistance Level $7.39 $3.65
Average True Range (ATR) 0.31 0.29
MACD 0.06 0.05
Stochastic Oscillator 15.75 43.80

Price Performance

Historical Comparison
SPT
RZLT

About SPT Sprout Social Inc

Sprout Social Inc develops a cloud software that brings together social messaging, data and workflows in a unified system of record, intelligence, and action. It has a centralized, secure and powerful platform that can scale horizontally across an organization to drive maximum business value. The firm generates majority revenue from software subscriptions. Geographically, the company operates in Americas, EMEA, and Asia Pacific, of which it derives maximum revenue from Americas.

About RZLT Rezolute Inc. (NV)

Rezolute Inc is a clinical-stage biopharmaceutical company focused on developing therapies for rare and metabolic diseases. The company aims to address unmet medical needs in conditions like congenital hyperinsulinism, a rare endocrine disorder causing excessive insulin production and resulting hypoglycemia. Rezolute's pipeline includes drug candidates designed to improve patient outcomes while reducing treatment burdens. The company engages in research, development, and clinical trials to advance its therapies and collaborates with medical communities and patient groups to support its objectives. Revenue and value creation depend largely on successful product development and regulatory approvals.

Share on Social Networks: